VKH
AEGR

Virtu KCG Holdings’s Aegerion Pharmaceuticals AEGR Stock Holding History

Virtu KCG Holdings’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-57,314
Closed -$212K – 3601
2016
Q1 		$212K Buy
+57,314
New +$355K 0.01% 2050
2014
Q1 		– Sell
-4,013
Closed -$285K – 4388
2013
Q4 		$285K Buy
+4,013
New +$307K ﹤0.01% 2655

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Virtu KCG Holdings's AEGR Position: Q2 2016 in Review

Virtu KCG Holdings sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 57,314 shares — an estimated $212K sold.

Virtu KCG Holdings first reported a position in AEGR in Q4 2013 and held it in 2 quarters. The position peaked at $285K in Q4 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Virtu KCG Holdings reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 57,314 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $212K.
  • Virtu KCG Holdings first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Virtu KCG Holdings's Aegerion Pharmaceuticals position peaked at $285K in Q4 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Virtu KCG Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.